Why U.S. Airlines Will Need to Lose the Hubris After We Bail Them Out

BioNTech (BNTX) Skyrockets on Coronavirus Vaccine Hopes; One Analyst Remains Cautious

Hopes for the swift development of a vaccine for the coronavirus got a boost on Monday.BioNTech (BNTX) announced that it will begin a global clinical development program called Project Lightspeed, for its COVID-19 mRNA-based vaccine, BNT162, in late April 2020. Fortunately, BioNTech's coronavirus vaccine program also got the hand it needs. The company has struck a strategic clinical development and commercialization deal with biotech Fosun Pharma. The China-based firm will retain the vaccine’s commercialization rights in China, while BioNTech will keep the rights for the rest of the world. The company will receive a $50 million investment from Fosun, in return for a holding of 1,580,777 shares in BioNtech (implying a price of $31.6 per share). On top of the welcome development, BioNTech also disclosed that it is currently in advanced talks with Pfizer concerning further development of the Vaccine outside China. Deal terms were not disclosed.In reaction, BioNTech shares skyrocketed...